TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/11/23 17:08 | 5/10/23 | GLYC | Glycomimetics Inc | DE | Health | Drug | Pharmaceutical Preparations | Junius Daniel M | MD | D | P | 47 | 1.56 | 0 | 30 | 47 | 93 | D | |||||||||||||||
2/17/23 17:06 | 2/16/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | M.d | 452 | 206.62 | 0 | 2 | 275 | 3 | D | |||||||||||||||
2/17/23 17:06 | 2/16/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | S.d | -1,119 | 511.68 | 0 | -2 | -42 | 3 | D | |||||||||||||||
12/7/22 16:30 | 12/5/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | M.d | 488 | 160.28 | 0 | 3 | 3 | D | ||||||||||||||||
12/7/22 16:30 | 12/5/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | S.d | -1,294 | 424.91 | 0 | -3 | -51 | 3 | D | |||||||||||||||
11/18/22 16:01 | 11/17/22 | GLYC | Glycomimetics Inc | DE | Health | Drug | Pharmaceutical Preparations | Junius Daniel M | MD | D | P | 37 | 1.87 | 0 | 20 | 46 | 63 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |